Canadian pharmaceutical company Apotex Health Corp (TSX:APTX) announced on Monday the US launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version of Pfizer's INLYTA, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Renal cell carcinoma is the most common type of kidney cancer in adults and accounts for approximately 90% of kidney cancer diagnoses. Axitinab Tablets provide an additional FDA-approved treatment option for appropriate patients with advanced RCC following failure of one prior systemic therapy.
Axitinib Tablets are supplied as 1 mg tablets in bottles of 180 (NDC 60505-4427-8) and 5 mg tablets in bottles of 60 (NDC 60505-4428-6).
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m